- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Drug Spend, Pricing, and Development
During this segment, the managed care stakeholders discuss drug spending in oncology and its relation to overall costs of cancer care. Additionally, they consider which stakeholders should work with pharmaceutical companies during the early stages of drug development, and to what degree stakeholders should collaborate with pharma.
Despite their high costs, newly emerging oncology drugs make up only 20% to 25% of overall oncology spend, and certain treatments may be associated with savings when total costs of care are considered, notes Brian Kiss, MD. For instance, some treatment options are associated with reduced length of hospitalization. However, Michael Kolodziej, MD, says that within his organization, data have demonstrated that this percentage is 35%.
Dr Kolodziej explores the impact of new, high-cost agents such as PD-1/PD-L1 drugs as treatment options for different types of cancer and discusses treatment effectiveness and appropriate drug pricing.
The use of contracting may result in innovation in terms of payment for drugs, comments Scott Gottlieb, MD. On the other hand, current government regulations stifle this innovation.
Continuing the discussion, Bruce Feinberg, DO, asks Dr Gottlieb to consider which stakeholders should work with pharmaceutical companies during the early stages of drug development.
Currently, large pharmaceutical companies are working alongside payers during the development of new drugs by providing information needed to make coverage decisions, notes Dr Gottlieb. Although discussions with payers are important, he adds, pharmaceutical companies should also work with consolidated delivery systems during drug development.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
